FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to new Exenatid analogues of general formula H-HisGlyGluGlyThrPheThrSerAspLeuSerLysGlnNleGluGluGluAlaValArgLeuPhe-IleGluTrpLeuLysAsnGlyGlyProSerSerGlyXProProProSer-ol where X is selected from L-Ala or D-Ala. The produced analogues show the stability higher than Exenatid, high insulinotropic activity, and also have high activity on renal sodition discharge without potassium ion loss, intensifis calcium and magnesium ion discharge, osmotically free water dishcarge. These properties can be effective for water-salt metabolism rebalancing along with glycemia normalisation.
EFFECT: production of the compositions which can be used for treatment of diabetes, and also for treatment and prevention of diabetic nephropathy and cardiac failure.
3 cl, 7 dwg, 4 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PEPTIDE FOR MEDICAL TREATMENT OF PANCREATIC DIABETES OF 2ND TYPE AND ITS COMPLICATIONS | 2014 |
|
RU2573933C1 |
| METHODS OF DIABETES TREATMENT AND BODY WEIGHT REDUCTION | 2006 |
|
RU2421237C2 |
| EXENATIDE AND DALARGIN DRUG FOR TREATING DIABETES, ADMINISRATION AND THERAPY | 2007 |
|
RU2413528C2 |
| METHOD OF TREATING INSULIN-INDEPENDENT DIABETES AND OBESITY, OSMOTIC DELIVERY SYSTEM AND METHOD FOR MAKING IT | 2008 |
|
RU2440097C2 |
| GLP-1 ANALOGUE DERIVATIVE OR ITS PHARMACEUTICALLY ACCEPTABLE SALTS AND THEREOF APPLICATION | 2010 |
|
RU2565536C2 |
| METHOD FOR INHIBITING GLUCAGON | 2000 |
|
RU2247575C9 |
| METHODS FOR DELIVERY OF NEUROPROTECTIVE POLYPEPTIDE TO CENTRAL NERVOUS SYSTEM | 2017 |
|
RU2790566C2 |
| DERIVATIVE OF INSULINOTROPIC PEPTIDE THAT CONTAINS MODIFIED N-ENDED AMINOACID | 2008 |
|
RU2442792C2 |
| METHOD FOR PRODUCING PEPTIDE EXENATIDE | 2011 |
|
RU2458066C1 |
| INSULINOTROPIC PEPTIDE DERIVATIVE WITH MODIFIED N-TERMINAL CHARGE | 2014 |
|
RU2673179C2 |
